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OBJECTIVES: To evaluate the prevalence of cancer and calculate annual health 
care expenditures for patients self-reported with cancer using a large  
US database. METHODS: The 2009 Medical Expenditure Panel Survey, a 
nationally representative survey of the US population was used to evaluate the 
prevalence and health care expenditure for patients self-reported with cancer. 
All patients over 17 years of age and diagnosed with any type of cancer was 
included in the study. The data was descriptively evaluated based on patient 
demographics and insurance type. RESULTS: The total patient population 
identified in this study was 36,855. Of these, 2,113 (5.7%) patients were diagnosed 
with some type of cancer. The study identified 27 different types of cancers  
and the top three highly prevalent cancers were: breast cancer (0.91%), skin non-
melanoma (0.88%) and prostate cancer (0.69%). The cancers that were more 
common in females than in males were bone, larynx, lymphoma, soft tissue, 
pancreas, stomach and thyroid. The mean patient total income reported was 
$29,583±20,696 and the median income was $20,512. The mean total family 
income reported was $56,254±52,729 and the median was $39,646. The highest 
mean total health care charges were for rectum ($92,022±146,618), pancreas 
($64,040±62,297) and leukemia ($54,193±84,300). The mean total amount 
reimbursed by Medicare, Medicaid, and Private Health Insurance for all cancer 
types were $4,719±12,589, $1,209±7,106 and $3,415±11,043 respectively. The  
mean total amount paid by patient out of the total health care charges  
was $1,271±3,342. The mean total percentage paid by Medicare, Medicaid and 
Private Health Insurance out of total health care charges for all cancer types 
were 19.06%, 4.88% and 13.79% respectively. CONCLUSIONS: The prevalence of 
cancer among the overall population was higher than the literature findings. 




COST ANALYSIS OF 18FDG-PET/CT AT THE PERSPECTIVE OF BRAZILIAN HEALTH 
CARE SYSTEM AS SERVICE PROVIDER: STUDY IN A PUBLIC HEALTH UNIT IN 
RIO DE JANEIRO  
Biz AN1, Schluckebier LF2, Bastos CRG1, Silva RM1, Carneiro MP2, Caetano R1 
1Rio de Janeiro State University, Rio de Janeiro, Brazil, 2Brazilian National Cancer Institute 
(INCA), Rio de Janeiro, Brazil  
OBJECTIVES: To estimate the cost of PET/CT procedure with 18FDG as its 
radiotracer from the perspective of a Brazilian public provider of health services, 
in order to support economic evaluation studies about the technology. 
METHODS: The micro-costing technique was used, and all inputs consumed in 
the activities involved with the procedure have been identified, measured and 
valuated. This included capital costs, human resources, radiopharmaceutical 
18FDG purchases, administrative costs and others. Data for cost estimates were 
collected from the observation of 85 exams at the Brazilian National Cancer 
Institute (INCA) from March to June 2012. The reference case considered adult 
cancer patients, daily production of 5 exams using one FDG dose per patient. 
INCA employees, because of their research activities, receive differentiated 
wages (from Science and Technology –S&T- career), than the usual employees of 
federal public hospitals where new PET/CTs might be installed receive (from 
Ministry of Health -MoH). So, to avoid biases, two cost estimates were carried out 
considering different wage modalities (MoH and S&T career). Also, sensitivity 
analysis examined elements that might impact on the costs in public health 
institutions. RESULTS: The average costs of the procedure for the reference case 
were US$1612.23 for Science and Technology career’s wages, and US$1498.05 for 
Ministry of Health’s wages. When a scenario of full capacity of exams was 
considered (10 procedures/day), average costs were significantly smaller: 
US$1023.47 for S&T and US$966.38 for MoH. The largest factors of impact on 
costs were daily volume of procedures, human resources, and price of 18FDG. 
CONCLUSIONS: Despite its growing applicability in diagnosis, the technology is 
still complex and aggregate high costs on health system. This is the first study 
which estimates cost of PET/CT technic in Brazil. PET procedure is in the pipeline 
to be reimbursed and this study could contribute to the reference value 
construction.  
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PCN92  
A RETROSPECTIVE DATABASE ANALYSIS OF MEDICATION ADHERENCE 
AMONG PATIENTS RECEIVING SYSTEMIC FIRST LINE ORAL THERAPY FOR 
HEPATOCELLULAR CARCINOMA (HCC)  
Mallick R, Cai J 
Daiichi Sankyo Inc, Parsippany, NJ, USA  
OBJECTIVES: With increasing use and cost of oral oncology medications, patient 
non-adherence with oral therapy is of greater concern. This study sought to 
evaluate the magnitude and predictors of non-adherence among patients 
receiving oral therapy for HCC accounting for patient-level variation in total 
duration of treatment and dose-changes. METHODS: This retrospective cohort 
study used an employer-based, commercially available, large claims database 
(2005-2011) to identify adult patients with ≥ 2 diagnoses of HCC (ICD-9 155), and  
≥2 filled prescriptions for sorafenib - the only approved oral therapy for HCC. 
Additional study inclusion criteria were not having other previous cancers, and a 
3-month wash-out period of no systemic therapy prior to the incident sorafenib 
fill (index) date. Adherence was assessed using a modified Proportion of Days 
Covered (PDC) measure over a patient-specific period from index date to 
treatment discontinuation. Non-adherence was categorized as PDC < 85% (base 
case), with two-way sensitivity analyses using an 80% cut-off and allowance for 
gaps due to dose change/Adverse Events. Logistic models were estimated to 
identify predictors of non-adherence. RESULTS: A total of 1,100 patients (median 
age = 61 years; 78% male) met eligibility criteria. Median sorafenib 30-day co-pay 
was $25 (5% > $500). 25% of patients had prior procedures. Median total sorafenib 
exposure was 120 days (Q1=68; Q3=223). 14.5% and 13.5% patients had down/up-
titrated fills from median index dose of 800 mg/day and 400 mg/day respectively. 
Median PDC was 98%; 15% of patients were non-adherent. Younger (below-
median) age (OR=1.5; p=0.02) and prior procedures (OR=1.7; p=0.003) were robust 
predictors of non-adherence. CONCLUSIONS: Using a modified PDC approach to 
account for varying and relatively short durations of treatment until 
progression/death in HCC, over 15% of patients were found non-adherent. 
Evidence on the predictors of non-adherence should be confirmed in the context 
of other, newly emerging oral therapies and may guide patient education and 
other compliance-enhancing initiatives.  
 
PCN93  
OBSERVED ABIRATERONE ACETATE UTILIZATION BY PROSTATE CANCER (PC) 
PATIENTS IN A LARGE ADMINISTRATIVE CLAIMS DATABASE IN THE UNITED 
STATES  
Lafeuille MH1, Dean J2, Lefebvre P1, Ellis L3, Senbetta M3 
1Groupe d’analyse, Ltée, Montréal, QC, Canada, 2Analysis Group, Inc, Boston, MA, USA, 3Janssen 
Scientific Affairs, LLC, Horsham, PA, USA  
OBJECTIVES: Abiraterone acetate is a CYP17 inhibitor indicated for treatment of 
patients with metastatic castration-resistant PC in combination with prednisone. 
The recommended dose is 1000mg (four 250mg tablets) administered once daily 
in combination with prednisone 5mg administered twice daily. This study 
evaluated U.S. real world abiraterone acetate utilization patterns in PC patients 
during the first year of commercial abiraterone acetate availability. METHODS: 
Prometis administrative claims data (6/2009 - 5/2012) were used to identify 
patients with ≥1 PC diagnosis (ICD-9 185.xx, V10.46) and ≥6 months of claims 
activity before their first abiraterone acetate prescription (index date). Population 
characteristics, number of abiraterone acetate fills, daily dose, refill interval, and 
Medication Possession Ratio (MPR) were summarized with descriptive statistics 
(n, %, mean±SD, median). RESULTS: A total of 1,545 PC patients with ≥1 
abiraterone acetate prescription and prerequisite claims activity were identified. 
The majority were ≥65 years of age; 82% were treated by an oncologist; 58% had 
abiraterone acetate claims covered by commercial insurance and 38% by 
Medicare; 49% had ≥6 months of post-index clinical activity. The median 
abiraterone acetate dose was 1,000 mg (mean±SD =995.6±48.6 mg). The median 
refill interval was 29.8 days between dispensings (mean±SD=34.3±16.4 days). 
MPR was 0.96±0.10. CONCLUSIONS: This retrospective study of early abiraterone 
acetate utilization in a large cohort of PC patients showed median abiraterone 
acetate dosing and refill intervals consistent with the product label.  
 
PCN94  
MEDICATION ADHERENCE STUDIES IN THE ERA OF ORAL TYROSINE KINASE 
INHIBITORS: A SYSTEMATIC LITERATURE SEARCH  
MacLean EA1, Wen L2, Borham A3 
1Pfizer, Inc., Wakefield, RI, USA, 2Pfizer, Inc., Houston, TX, USA, 3Pfizer, Inc., San Francisco, CA, 
USA  
OBJECTIVES: Potential for poor medication adherence to oral oncology agents is 
often discussed, but many papers on the subject are review articles and 
treatment periods cited often precede the era of oral tyrosine kinase inhibitors 
(TKIs). Our objective was to assess the landscape of studies published in the era 
of TKIs that assessed real world patient adherence as a main objective. 
METHODS: We searched PubMed in July 2012 for English language papers with 
the following limits applied: English, Humans, Last 10 years and used the MeSH 
terms “medication adherence” and “neoplasms” in addition to separate searches 
using the terms “patient compliance” or “patient adherence” or “patient non-
compliance” or “patient non-adherence” or “non-compliance” or “non-
adherence”and “drug therapy” or “medication”, and “neoplasms” and “oral”. 
RESULTS: Resulting citations (n=595) were searched for primary research articles 
with an objective of assessing adherence in adults taking oral oncolytics outside 
of a clinical trial (n=44). Bibliographies of these studies were reviewed and 
revealed 10 additional studies. Papers not reporting or with poorly described 
methods of assessing adherence were excluded as were those assessing 
adherence by proxy. Of the 54 papers, 43 were included. Over half (58%) included 
patients with breast cancer, 23% with CML, 16% studied multiple tumor types 
and 1 was in gastrointestinal stromal tumor. Data sources consisted mostly (51%) 
of secondary databases with patient self report either verified or unverified also 
common (28%). More than half (56%) were of retrospective cohort design. Most 
studied hormonal therapies (49%), 23% studied TKIs imatinib, dasatinib or 
nilotinib, 21% studied multiple drug classes and 3 studied capecitabine. 
CONCLUSIONS: Since the introduction of oral TKIs, most studies of real world 
adherence to oral oncology agents have been in breast cancer patients and 
studied hormonal therapies. Published studies of adherence to TKIs have 
focused on very few agents.  
 
PCN95  
ADHERENCE AND ITS ASSOCIATION WITH HEALTH OUTCOMES AMONG 
PATIENTS CURRENTLY TREATED FOR LEUKEMIA, MELANOMA, OR NON-SMALL 
CELL LUNG CANCER (NSCLC)  
Goren A1, DiBonaventura M1, Wagner R2 
1Kantar Health, New York, NY, USA, 2Kantar Health, Montrouge, France  
OBJECTIVES: Cancer treatment is rapidly evolving with the emergence of highly 
effective oral targeted therapies, which has elevated the importance of 
adherence. This study examined the rates and effect of real-world non-
adherence from a patient perspective among those using treatments where such 
oral therapies are the standard of care. METHODS: Data from the 2012 U.S. 
National Health and Wellness Survey were analyzed. Patients who reported a 
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diagnosis of either leukemia, melanoma, or non-small cell lung cancer (NSCLC) 
and reported currently using a treatment for their condition were included in the 
analyses. Adherence was measured using the Morisky Medication Adherence 
Scale (MMAS-8) modified for use in oncology. Sociodemographics, health history, 
and health outcomes were also assessed. Descriptive analyses of adherence were 
conducted along with an assessment of the relationships between adherence 
and health outcomes. RESULTS: A total of 103 respondents were included in the 
analyses (n=42, 41, and 20 for leukemia, melanoma, and NSCLC, respectively). 
Most respondents were male (69.9%) and the mean age was 57.1 years (SD=15.79). 
Across the three tumor types 65.0% of respondents reported some form of non-
adherent behavior (71.4%, 58.5%, and 65.0% for leukemia, melanoma, and NSCLC, 
respectively). Pooling tumor types, patients who were non-adherent reported 
significantly worse mental health status compared with patients who were 
adherent (Mean=44.41 vs. 49.48, p<.05). Similar trends (though only marginally 
significant) were observed for hospitalizations (Mean=0.97 vs. 0.42, p=.11) and 
emergency room visits (Mean=1.18 vs. 0.25, p=.07) in the past six months. 
CONCLUSIONS: These results suggest a significant level of non-adherence 
among patients being treated for leukemia, melanoma, and NSCLC. Although 
statistical power was modest due to small sample size, preliminary results 
suggest a deleterious effect of non-adherence on health outcomes. As more oral 
targeted therapies emerge, an emphasis should be placed on improving 
adherence rates to maximize treatment benefit and reduce societal costs.  
 
PCN96  
INDICATORS OF PARTICIPATION IN CERVICAL CANCER SCREENING AMONG 
WOMEN IN A HUNGARIAN TOWN, NAGYATÁD  
Vajda R1, Horváthné Kívés Z1, Boncz I1, Ágoston I1, Molics B1, Karamánné Pakai A2 
1University of Pécs, Pécs, Hungary, 2University of Pécs, Zalaegerszeg, Hungary  
OBJECTIVES: The aim of our study was to evaluate a sample of the population’s 
knowledge on cervical smear test and HPV, also learn about the vaccine, 
attitudes towards screening, the appearance at screening or absence 
motivations. METHODS: A quantitative cross-sectional, questionnaire survey 
was carried out among the mothers of girls aged nine to fourteen years in the 
public school of Nagyatád town in September 2012. In total, 247 questionnaires 
were distributed, of which 186 proved to be evaluated. The χ2-test was performed 
as a statistical method besides 95% probability (p<0.05). The data analysis was 
performed with SPSS 20.0 programs. RESULTS: 96.2% of the respondent women 
have had cervical smear tests. Their average age was 20.92 years when they went 
for the first time for cervical cancer screening. 84.4% of respondent women 
reported annual visit for screening. 49.2% of respondent women last appeared in 
2012, while 40.2% in 2011 at gynecologist. College graduates were significantly (χ2 
= 13.785, p = 0.032) less likely to take part on screening over two years interval. 
Most of their knowledge on the prevention of cervical cancer obtained from 
television (67.7%), gynecologist (58.6%), Internet (47.8%) or newspapers (36%). 
Only 8.1% had heard of the disease in the form of lectures. CONCLUSIONS: 
Women reported a very high participation rate at cervical cancer screening. 
Although there is a three years screening interval in Hungary, most of the 
women in our study reported a two years or less screening interval.  
 
PCN97  
UTILITY VALUES FOR SPECIFIC CHRONIC MYELOGENOUS LEUKAEMIA (CML) 
CHRONIC PHASE HEALTH STATES ELICITED FROM THE GENERAL PUBLIC IN 
THE UNITED KINGDOM  
Guest J1, Gray L2, Szczudlo T3, Magestro M3 
1Catalyst Health Economics Consultants, Northwood, Middx, UK, 2Novartis Pharmaceuticals UK 
Limited, Frimley, Surrey, UK, 3Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA  
OBJECTIVES: To elicit utility values for CML chronic phase health states (i.e. 
molecular response (MR), complete molecular response (CMR) [i.e. undetectable 
disease on treatment], treatment-free remission (TFR) and re-appearance of 
detectable disease (RDD) [i.e. relapse from treatment-free remission to molecular 
response requiring treatment]) from the general public in the UK. METHODS: 
Interviewer-administered time trade-off (TTO) and standard gamble (SG) utilities 
were elicited for four CML-related health states from a random sample of 235 
members of the general public in the UK, using health state descriptions 
validated by clinicians and members of the general public. RESULTS: 
Respondents’ mean age was 61 years and 47% were female. Mean utilities were: 
0.90 (TTO) and 0.72 (SG) for RDD, 0.94 (TTO) and 0.80 (SG) for MR, 0.96 (TTO) and 
0.85 (SG) for CMR and 0.97 (TTO) and 0.87 (SG) for TFR. SG values were all 
significantly lower than TTO values (p <0.001). TTO values for TFR and CMR were 
significantly different from that for RDD (p = 0.002). The SG value for TFR was 
significantly different from that for MR and RDD (p <0.001). Additionally, the SG 
value for MR was significantly different from that for CMR (p = 0.02) and RDD (p 
<0.001). Respondents’ preference values for any of the states were not affected by 
their demographics, except SG values elicited from males which were ~0.08 
higher than those from females (p <0.05). CONCLUSIONS: These findings 
suggests that level of response to treatment impacts on patients’ health-related 
quality of life in CML. Health states associated with a better outcome (e.g. TFR) 
were associated with a higher preference value than states with a poorer 
outcome (e.g. RDD). These utility values can be used to estimate quality-adjusted 
life years associated with different treatment options.  
 
PCN98  
IMPORTANCE, ANTICIPATED BURDEN, AND FUNCTION: VALIDITY OF 
UTILITIES FOR IMPOTENCE AND URINARY INCONTINENCE  
Cantor SB1, Deshmukh AA1, Krahn MD2, Volk RJ1 
1University of Texas M.D. Anderson Cancer Center, Houston, TX, USA, 2Toronto Health 
Economics and Technology Assessment (THETA) Collaborative, Toronto, ON, Canada  
OBJECTIVES: To determine the relationship between a man’s current urinary and 
sexual function, qualitative valuations of future loss of function, and preferences 
for potential urinary and sexual impairment should he undergo screening or 
treatment for prostate cancer. METHODS: We elicited time-tradeoff utilities for 
prostate cancer treatment outcomes from 168 men. We performed logistic 
regression to (1) analyze the relationships between current function, valuation of 
future loss of function, and preferences, and (2) identify the relationship between 
the qualitative responses and the optimal decision of whether to undergo 
screening for prostate cancer as determined from a previously-published 
decision-analytic model. RESULTS: Current function was not related to 
impotence and urinary incontinence utilities. Importance of sexual function and 
anticipated adjustment to a loss of sexual function were strongly related to 
impotence utilities (P<0.05). Greater perceived difficulty adjusting to loss of 
bladder control, an anticipated function, was significantly related to 
incontinence utilities. Based on the multivariate analysis, significant predictors 
for the utility of severe incontinence were family income (OR=0.26 [CI 0.08-0.87] 
for income $20k-$70k and OR=0.11 [CI 0.01-0.70] for income >$70k, relative to 
income group <$20k), family history of prostate cancer (OR=2.85 [CI 0.96-8.45]), 
work status (OR=2.90 [CI 0.99-8.50]), and attitude toward needing to wear an 
incontinence pad (OR=6.47 [CI 0.76-54.4]). However, no variables were significant 
predictors for the complete impotence utilities. The importance of sexual 
functioning, with odds of 2.99 ([CI 1.28-6.95]), was a significant predictor of the 
optimal decision to screen. CONCLUSIONS: Current function and satisfaction are 
not necessarily useful as proxy measures of utility; however, anticipated 
difficulty adjusting to adverse health effects were highly related to preferences. 
Similarly, the importance of sexual functioning, a future preference, was related 
to the optimal decision, which validates our previously published decision-
analytic model.  
 
PCN99  
OBESITY ASSOCIATED WITH ADDED BURDEN AMONG PATIENTS WITH 
CANCER IN THE 2012 NATIONAL HEALTH AND WELLNESS SURVEY IN THE 
UNITED STATES  
Goren A1, Philip EJ2 
1Kantar Health, New York, NY, USA, 2Memorial Sloan-Kettering Cancer Center, New York, NY, 
USA  
OBJECTIVES: Excess weight is associated with poorer disease outcomes across 
various cancers. The current study examined health outcomes associated with 
obesity in respondents with and without cancer, addressing a lack of large-scale, 
population-based research including non-cancer comparison groups. METHODS: 
Among 71,149 U.S. 2012 NHWS respondents, 7,751 reported diagnosis with 
cancer: any/metastatic solid tumor, leukemia, lymphoma, breast, cervical, 
colorectal, ovarian, prostate, skin, uterine, other, small cell lung, and/or non-
small cell lung cancer. Cancer diagnosis and obesity (BMI≥30 vs. less) were 
crossed for analysis, resulting in 69,292 respondents (excluding 1,857 without 
BMI information): 2,745 obese versus 4,860 non-obese with cancer and 20,177 
obese versus 41,510 non-obese without cancer. Health outcomes included Work 
Productivity and Activity Impairment questionnaire-based measures (among 
employed-only for work productivity), and Mental and Physical Component 
Summary (MCS and PCS) scores and health utilities (SF-6D) from the SF-36v2. 
Bivariate tests of column proportions and means for categorical and continuous 
variables, respectively, compared measures across all groups. Multivariable 
(linear and negative binomial) generalized linear models assessed outcomes as a 
function of obesity, cancer diagnosis, their interaction, and sociodemographic 
and health behavior covariates of interest, plus Charlson comorbidity index (CCI) 
scores. RESULTS: Respondents with versus without cancer were older and had 
higher CCI (as did obese versus non-obese respondents), all p<0.05. Adjusting for 
covariates, obesity versus no obesity was associated (among those with cancer) 
with decreases in PCS (-3.61 points) and utilities (-0.030) and increases in 
presenteeism-related (20%), overall work (18%), and activity (24%) impairment, 
all p<0.05. CCI was associated with significant impairments across outcomes, all 
p<0.001. CONCLUSIONS: Among cancer-diagnosed respondents, obesity was 
associated with significant impairments. Obese respondents with cancer also 
had a higher rate of comorbidity. Obesity and a history of cancer may represent a 
”dual-risk” profile, suggesting the need for coordinated follow-up care and health 
promotion in this population.  
 
PCN100  
COMPARISON OF PATIENT REPORTED OUTCOMES (PROS) AND CLINICIAN 
REPORTED OUTCOMES (CROS) IN PATIENTS WITH METASTATIC BRAIN 
DISEASE  
Taychakhoonavudh S1, Franzini L1, Lal L1, Chang E2, Meyers CA3, Wefel JS3, Swint JM1 
1The University of Texas School of Public Health, Houston, TX, USA, 2Keck School of Medicine of 
USC, USC Norris Cancer Hospital, Keck Hospital of USC Los Angeles County + USC Medical 
Center, Los Angeles, CA, USA, 3The University of Texas MD Anderson Cancer Center, Houston, 
TX, USA  
OBJECTIVES: To evaluate the concordance between Neurocognitive function 
(NCF), Karnofsky performance status (KPS), quality of life and time trade-off 
(TTO) over time. METHODS: We retrospectively analyzed secondary data from a 
randomized study of 58 patients who completed tests determining TTO utility 
with each of three time horizons (10 years, 5 years, and 1 year), neurocognitive 
function (Hopkins Verbal Learning Test–Revised [HVLT-R] and Trail Making Test 
Part B), KPS score, and quality of life (Functional Assessment of Cancer Therapy–
Brain [FACT-BR]) and symptoms (MD Anderson Symptom Inventory–Brain Tumor 
[MDASI-BT]) at baseline and at predetermined intervals for 2 years. Multiple 
linear regression analyses were used to estimate the relationships between TTO 
utility and other outcome variables, including a time variable to capture within-
patient change over time. RESULTS: Significant but weak associations were 
